WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (106)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fumagalli, F.
Right arrow Articles by Caron, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fumagalli, F.
Right arrow Articles by Caron, M. G.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*d-METHAMPHETAMINE
*DOPAMINE
*RESERPINE
Medline Plus Health Information
*Methamphetamine

 Previous Article  |  Next Article 

The Journal of Neuroscience, April 1, 1999, 19(7):2424-2431

Increased Methamphetamine Neurotoxicity in Heterozygous Vesicular Monoamine Transporter 2 Knock-Out Mice

Fabio Fumagalli, Raul R. Gainetdinov, Yan-Min Wang, Kenneth J. Valenzano, Gary W. Miller, and Marc G. Caron

Howard Hughes Medical Institute Laboratories, Departments of Cell Biology and Medicine, Duke University Medical Center, Durham, North Carolina 27710

Methamphetamine (METH) is a powerful psychostimulant that is increasingly abused worldwide. Although it is commonly accepted that the dopaminergic system and oxidation of dopamine (DA) play pivotal roles in the neurotoxicity produced by this phenylethylamine, the primary source of DA responsible for this effect has remained elusive. In this study, we used mice heterozygous for vesicular monoamine transporter 2 (VMAT2 +/- mice) to determine whether impaired vesicular function alters the effects of METH. METH-induced dopaminergic neurotoxicity was increased in striatum of VMAT2 +/- mice compared with wild-type mice as revealed by a more consistent DA and metabolite depletion and a greater decrease in dopamine transporter expression. Interestingly, increased METH neurotoxicity in VMAT2 +/- mice was accompanied by less pronounced increase in extracellular DA and indices of free radical formation compared with wild-type mice. These results indicate that disruption of vesicular monoamine transport potentiates METH-induced neurotoxicity in vivo and point, albeit indirectly, to a greater contribution of intraneuronal DA redistribution rather than extraneuronal overflow on mediating this effect.

Key words: vesicular monoamine transporter; methamphetamine; dopamine; microdialysis; GFAP; free radicals

Copyright © 1999 Society for Neuroscience  0270-6474/99/1972424-08$05.00/0


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Cui, R. Aras, W. V. Christian, P. M. Rappold, M. Hatwar, J. Panza, V. Jackson-Lewis, J. A. Javitch, N. Ballatori, S. Przedborski, et al.
The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway
PNAS, May 12, 2009; 106(19): 8043 - 8048.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. J. Volz, S. J. Farnsworth, S. D. Rowley, G. R. Hanson, and A. E. Fleckenstein
Methylphenidate-Induced Increases in Vesicular Dopamine Sequestration and Dopamine Release in the Striatum: The Role of Muscarinic and Dopamine D2 Receptors
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 161 - 167.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. J. Volz, S. J. Farnsworth, J. L. King, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein
Methylphenidate Administration Alters Vesicular Monoamine Transporter-2 Function in Cytoplasmic and Membrane-Associated Vesicles
J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 738 - 745.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
W. M. Caudle, J. R. Richardson, M. Z. Wang, T. N. Taylor, T. S. Guillot, A. L. McCormack, R. E. Colebrooke, D. A. Di Monte, P. C. Emson, and G. W. Miller
Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration
J. Neurosci., July 25, 2007; 27(30): 8138 - 8148.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
T.-K. Sang, H.-Y. Chang, G. M. Lawless, A. Ratnaparkhi, L. Mee, L. C. Ackerson, N. T. Maidment, D. E. Krantz, and G. R. Jackson
A Drosophila Model of Mutant Human Parkin-Induced Toxicity Demonstrates Selective Loss of Dopaminergic Neurons and Dependence on Cellular Dopamine
J. Neurosci., January 31, 2007; 27(5): 981 - 992.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. S. Rau, E. Birdsall, T. J. Volz, J. A. Riordan, A. J. Baucum II, B. P. Adair, R. Bitter, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein
Methamphetamine Administration Reduces Hippocampal Vesicular Monoamine Transporter-2 Uptake
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 676 - 682.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
W. M. Caudle, J. R. Richardson, K. C. Delea, T. S. Guillot, M. Wang, K. D. Pennell, and G. W. Miller
Polychlorinated Biphenyl-Induced Reduction of Dopamine Transporter Expression as a Precursor to Parkinson's Disease-Associated Dopamine Toxicity
Toxicol. Sci., August 1, 2006; 92(2): 490 - 499.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. R. Richardson, W. M. Caudle, M. Wang, E. D. Dean, K. D. Pennell, and G. W. Miller
Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease
FASEB J, August 1, 2006; 20(10): 1695 - 1697.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. G. Truong, D. G. Wilkins, J. Baudys, D. J. Crouch, K. L. Johnson-Davis, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein
Age-Dependent Methamphetamine-Induced Alterations in Vesicular Monoamine Transporter-2 Function: Implications for Neurotoxicity
J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1087 - 1092.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. J. Eyerman and B. K. Yamamoto
Lobeline Attenuates Methamphetamine-Induced Changes in Vesicular Monoamine Transporter 2 Immunoreactivity and Monoamine Depletions in the Striatum
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 160 - 169.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Eisenhofer, I. J. Kopin, and D. S. Goldstein
Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine
Pharmacol. Rev., September 1, 2004; 56(3): 331 - 349.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. L. Johnson-Davis, J. G. Truong, A. E. Fleckenstein, and D. G. Wilkins
Alterations in Vesicular Dopamine Uptake Contribute to Tolerance to the Neurotoxic Effects of Methamphetamine
J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 578 - 586.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. L. CADET, S. JAYANTHI, and X. DENG
Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis
FASEB J, October 1, 2003; 17(13): 1775 - 1788.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
F. Fornai, P. Lenzi, M. Gesi, M. Ferrucci, G. Lazzeri, C. L. Busceti, R. Ruffoli, P. Soldani, S. Ruggieri, M. G. Alessandri, et al.
Fine Structure and Biochemical Mechanisms Underlying Nigrostriatal Inclusions and Cell Death after Proteasome Inhibition
J. Neurosci., October 1, 2003; 23(26): 8955 - 8966.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
V. Sandoval, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein
Methylphenidate Alters Vesicular Monoamine Transport and Prevents Methamphetamine-Induced Dopaminergic Deficits
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1181 - 1187.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. L. Unger, P. Mazzola-Pomietto, D. L. Murphy, and A. M. Andrews
2'-NH2-MPTP [1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] Depletes Serotonin and Norepinephrine in Rats: A Comparison with 2'-CH3-MPTP [1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine]
J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 527 - 533.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
K. E. Larsen, E. A. Fon, T. G. Hastings, R. H. Edwards, and D. Sulzer
Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis
J. Neurosci., October 15, 2002; 22(20): 8951 - 8960.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. P. Hansen, E. L. Riddle, V. Sandoval, J. M. Brown, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein
Methylenedioxymethamphetamine Decreases Plasmalemmal and Vesicular Dopamine Transport: Mechanisms and Implications for Neurotoxicity
J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1093 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Heller, N. Bubula, R. Lew, B. Heller, and L. Won
Gender-Dependent Enhanced Adult Neurotoxic Response to Methamphetamine following Fetal Exposure to the Drug
J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 769 - 779.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. B. Harrod, L. P. Dwoskin, P. A. Crooks, J. E. Klebaur, and M. T. Bardo
Lobeline Attenuates d-Methamphetamine Self-Administration in Rats
J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 172 - 179.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. M. Brown, G. R. Hanson, and A. E. Fleckenstein
Regulation of the Vesicular Monoamine Transporter-2: A Novel Mechanism for Cocaine and Other Psychostimulants
J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 762 - 767.
[Abstract] [Full Text]

Home page
 FASEB J.Home page
G. R. UHL, S. LI, N. TAKAHASHI, K. ITOKAWA, Z. LIN, M. HAZAMA, and I. SORA
The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins
FASEB J, December 1, 2000; 14(15): 2459 - 2465.
[Abstract] [Full Text]

Home page
 J. Neurosci.Home page
T. Xie, U. D. McCann, S. Kim, J. Yuan, and G. A. Ricaurte
Effect of Temperature on Dopamine Transporter Function and Intracellular Accumulation of Methamphetamine: Implications for Methamphetamine-Induced Dopaminergic Neurotoxicity
J. Neurosci., October 15, 2000; 20(20): 7838 - 7845.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
X. Deng, B. Ladenheim, L.-I Tsao, and J. L. Cadet
Null Mutation of c-fos Causes Exacerbation of Methamphetamine-Induced Neurotoxicity
J. Neurosci., November 15, 1999; 19(22): 10107 - 10115.
[Abstract] [Full Text] [PDF]


-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-